TransCode Therapeutics financials
$1.63−4.68%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Gross margin | — | — | — | — | — |
| Operating income | -$28.0M | -$15.7M | -$19.4M | -$18.6M | -$6.2M |
| Net income | -$36.3M | -$16.8M | -$18.5M | -$17.6M | -$6.8M |
| Net margin | — | — | — | — | — |
| Diluted EPS | $-52.59 | $-1336.63 | $-2901.08 | $-1000497.96 | $-598752.00 |
| EBITDA | -$19.1M | -$15.6M | -$19.3M | -$18.5M | -$6.1M |
| Operating cash flow | -$19.5M | -$13.3M | -$18.1M | -$15.8M | -$5.3M |
| Free cash flow | -$19.5M | -$13.4M | -$18.1M | -$15.9M | -$5.5M |
| Diluted shares | 0.7M | 0.0M | 0.0M | 0.0M | 0.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $17.8M | $5.8M | $2.8M | $5.0M | $20.8M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $162.4M | $7.3M | $5.2M | $7.6M | $22.9M |
| Total liabilities | $10.5M | $9.3M | $3.5M | $4.3M | $2.5M |
| Shareholders' equity | $10.3M | -$2.0M | $1.6M | $3.2M | $20.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology